SP Group (SPG) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
20 Nov, 2025Executive summary
Revenue for the first nine months of 2025 declined by 3.3% year-over-year to DKK 2,122 million, with EBITDA down 6.7% and EBT down 9.8%.
Q3 2025 saw a 7.7% drop in revenue and a 13.1% decrease in EBITDA compared to Q3 2024.
Guidance for the full year is maintained, expecting results similar to 2024, with revenue guidance of -3% to +3% and EBITDA margin of 19%-21%.
Growth in subsupplier projects and new initiatives in Healthcare, Cleantech, and Defence are expected to drive future growth.
Leadership transition: new CFO to join in January 2026, with current CFO moving to a new role.
Financial highlights
9M 2025 revenue: DKK 2,122 million (down 3.3% year-over-year); EBITDA: DKK 417 million (down 6.7%); EBIT: DKK 270 million (down 8.9%).
Q3 2025 revenue: DKK 655 million; EBITDA: DKK 126 million; EBIT: DKK 77 million (down 17%).
Profit before tax (EBT) dropped by 9.8% to DKK 229 million; diluted EPS decreased by 8.8% to DKK 14.8.
Net interest-bearing debt reduced by DKK 98 million to DKK 723 million; equity at DKK 1.7 billion.
Cash flow from operations: DKK 328 million; investments: DKK 124 million; DKK 50 million each for share buybacks and dividends; DKK 100 million debt repayment.
Outlook and guidance
Full-year 2025 guidance maintained: revenue growth of -3% to +3%, EBITDA margin 19%-21%, EBT margin 11%-13%.
Q4 revenue target is ambitious but considered achievable based on Q1 performance and current order book.
Order book for Q4 is growing, but some risk of customer postponements into January remains.
U.S. factory expected to reach break-even in 2026 and be fully utilized by 2028-2029, with additional DKK 100 million investment planned.
Latest events from SP Group
- Strong H1 2024 growth, upgraded outlook, and international expansion led by healthcare sales.SPG
Q2 202423 Jan 2026 - Record revenue and margin growth in 2024; cautious 2025 outlook with focus on own products.SPG
Q4 202426 Dec 2025 - Acquisition enables in-house toolmaking, new materials, and DKK 20–25m annual synergies.SPG
M&A Announcement19 Dec 2025 - Record Q1 growth and margin gains led by Healthcare; outlook steady amid global risks.SPG
Q1 202524 Nov 2025 - Q2 slowdown led to lower H1 results and a flat outlook, but margins and investments remain strong.SPG
Q2 202523 Nov 2025 - 2025 guidance maintained as order backlog and new projects offset lower sales and margins.SPG
Q3 202520 Nov 2025 - H1 2025 saw revenue and earnings decline, but margin guidance and growth projects remain on track.SPG
Q2 202520 Aug 2025 - Strong own-brand and healthcare sales drove double-digit profit and margin growth in 2024.SPG
Q3 202413 Jun 2025 - Record Q1 growth and margin expansion, with 2025 outlook unchanged.SPG
Q1 20256 Jun 2025